Detalles de la búsqueda
1.
Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine.
J Infect Dis
; 223(11): 2001-2012, 2021 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33031517
2.
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
Hum Vaccin Immunother
; 18(1): 1-14, 2022 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34726574
3.
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Vaccine
; 40(1): 162-172, 2022 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34507861
4.
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
Hum Vaccin Immunother
; 17(8): 2678-2690, 2021 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019468
5.
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
Pediatr Infect Dis J
; 39(8): 763-770, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639460
6.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Hum Vaccin Immunother
; 15(3): 540-548, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30427749
7.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
Hum Vaccin Immunother
; 15(3): 530-539, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30648919
8.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
Vaccine
; 36(45): 6875-6882, 2018 10 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29559167
9.
Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
Hum Vaccin Immunother
; 12(8): 2135-2141, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27002793
10.
Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Pediatr Infect Dis J
; 34(2): 186-94, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25741971
11.
M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.
Vaccine
; 33(18): 2132-40, 2015 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25796337
12.
Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
Vaccine
; 33(24): 2793-9, 2015 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25913828
13.
Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults.
Vaccine
; 32(21): 2399-405, 2014 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24637174
Resultados
1 -
13
de 13
1
Próxima >
>>